3Dバイオプリンティング - SFから現実へ

学術界と産業界での15年以上に及ぶ研究開発の結果、いくつの3Dバイオプリンティングテクノロジーの主要アプリケーションが実現間近の状況にあります。IDTechExの新しいレポート「3Dバイオプリンティング 2017年 - 2027年: テクノロジー、マーケット、市場予測」では世界の3Dバイオプリンティング市場が2027年までには18億ドルに達すると予測されています。

 

3Dバイオプリンティングとは細胞の層を何層も積み重ね最終的に三次元（3D）の構造物を作り上げることと定義されています。生物学的に基本的な物質から形態および機能において天然の生物組織に極めて近いものを人工的に生成するという独自の機能を果たします。このように自然界の生物を模倣した製造を実現させると生理学の観点から有意義な成果が生まれ研究資源がより効率良く使えるようになるだけでなく、再生医療への応用も可能になります。後者に挙げた再生医療への応用は長い間3Dバイオプリンティングテクノロジーの最終的な目標とされてきましたが、3Dバイオプリンティングによる組織生成について動物実験では昨年有望な結果が得られました。このことは将来、人間についても損傷したり機能不全となったりした臓器を3Dバイオプリンティングで生成したものと単純に交換するようになる可能性を示唆しています。こんな筋書きがSF小説の中だけでなく現実となる時代がついにやってきました。

レポートのご注文はこちらから。また、請求書の発行も可能です。お問い合わせはIDTechEx日本法人 アイディーテックエックス株式会社 m.murakoshi@idtechex.com まで。お見積書も発行いたします。

 

In the short term, the next few years are set to be an exciting time of rapid expansion for the 3D bioprinting industry. Commercial interest in 3D bioprinting has risen greatly - already the first four months of 2017 has seen the release of three new affordable 3D bioprinters from manufacturers Aether, BioBots, and Cellink. Over the past year, 3D bioprinting service bureaus have experienced significant growth and are partnering with several multi-national corporations in the consumer products and pharmaceutical industries. IDTechEx report 3D Bioprinting 2017 - 2027: Technologies, Markets, Forecasts contextualises these activities, and discusses the key drivers of the 3D bioprinting industry as well as providing insight into the market trends observed.

 

One such market trend is the increasing versatility of 3D bioprinters. Users can now easily incorporate several 3D bioprinting technologies into their construct without involving a second or third machine. IDTechEx's new report profiles and benchmarks the four main 3D bioprinting technologies of inkjet, extrusion, laser-induced forward transfer, and microvalve printheads. The report details key specifications, technology subtypes, and includes a SWOT analysis of each printhead technology. Alternative technologies for the creation of 3D biological structures are also introduced in the report.

 

3D bioprinting has applications in several high value markets, and the greatest impact of 3D bioprinting is expected to be in regenerative medicine. However, the realisation of regenerative medicine solutions is not expected within the next decade. Current and future applications of 3D bioprinting covered in 3D Bioprinting 2017 - 2027: Technologies, Markets, Forecasts include the testing of cosmetics and other consumer goods, drug screening for the pharmaceutical industry, personalised medicine, regenerative medicine, cell-based biosensors, food and other animal products, education, academic research and bionics.

 

The recent increase in interest and excitement for 3D bioprinting bodes well for the future. In this report, IDTechEx forecasts that the overall 3D bioprinting market is set to reach $1.8 billion by the year 2027. This is driven by demand for both 3D bioprinters, and 3D bioprinted tissues, and additional 10-year forecasts for these product markets are included in the report. Though regenerative medicine is not expected to be a significant market within the next 10 years, it has and will be a major influence on the 3D bioprinting market. As such, a separate chapter of the report is dedicated to discussing the future for 3D bioprinting in regenerative medicine.

 

Readers of this new report by IDTechEx will gain a comprehensive view of the technologies, applications and markets of 3D bioprinting. Insights and knowledge of the industry were obtained through primary interviews with key stakeholders in 3D bioprinting companies, and these interviews also form the basis of the company profiles included at the end of the report.

 

For more see www.IDTechEx.com/3dbio